Evaluation of Ventricular Assist Devices and Cardiac Transplantation


Although majority of patients with heart failure can be treated medically for years with reasonable quality of life, some progress to advanced heart failure. Patients with end stage disease have very short life expectancy and multiple limitations in daily activities which compromise their quality of life. The choice then becomes between acceptance of the limitations, support with mechanically assisted circulation, or heart transplantation. While ventricular assist devices is the most dynamic and rapidly evolving part of the field, heart transplant remains a standard method with proven record of good long-term outcomes. The shortage of donor hearts makes the process of candidate selection very challenging. It includes medical, social, financial, and ethical consideration and always requires a team approach. In this chapter, we are summarizing the key points of the evaluation process for cardiac transplantation.


Advanced heart failure Mechanical circulatory support LVADs or Left Ventricular Assist Devices Destination Therapy Bridge to Transplant Therapy 


  1. 1.
    Miller LW. Left ventricular assist devices are underutilized. Circulation. 2011;123:1552–8; discussion 1558.CrossRefPubMedGoogle Scholar
  2. 2.
    Terracciano CM, Miller LW, Yacoub MH. Contemporary use of ventricular assist devices. Annu Rev Med. 2010;61:255–70.CrossRefPubMedGoogle Scholar
  3. 3.
    Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, Dobbels F, Rahmel AO, Hertz MI. The registry of the international society for heart and lung transplantation: twenty-seventh official adult heart transplant report–2010. J Heart Lung Transplant. 2010;29:1089–103.CrossRefPubMedGoogle Scholar
  4. 4.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the acc/aha 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American college of cardiology foundation/american heart association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol. 2009;53:e1–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Hfsa 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–194.CrossRefPubMedGoogle Scholar
  6. 6.
    Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds Jr LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778–86.CrossRefPubMedGoogle Scholar
  7. 7.
    Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the heart failure survival score for serial risk stratification in advanced heart failure. Am J Cardiol. 2005;95:734–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Peterson LR, Schechtman KB, Ewald GA, Geltman EM, Meyer T, Krekeler P, Rogers JG. The effect of beta-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. J Heart Lung Transplant. 2003;22:70–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Shaw LJ, Kargl D, Chaitman BR. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol. 1996;27:345–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, Guazzi M. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007;115:2410–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Chua TP, Ponikowski P, Harrington D, Anker SD, Webb-Peploe K, Clark AL, Poole-Wilson PA, Coats AJ. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997;29:1585–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Lucas C, Stevenson LW, Johnson W, Hartley H, Hamilton MA, Walden J, Lem V, Eagen-Bengsten E. The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. Am Heart J. 1999;138:618–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K, Barr M. Listing criteria for heart transplantation: international society for heart and lung transplantation guidelines for the care of cardiac transplant candidates–2006. J Heart Lung Transplant. 2006;25:1024–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Erickson KW, Costanzo-Nordin MR, O’Sullivan EJ, Johnson MR, Zucker MJ, Pifarre R, Lawless CE, Robinson JA, Scanlon PJ. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant. 1990;9:526–37.PubMedGoogle Scholar
  16. 16.
    Chen JM, Levin HR, Michler RE, Prusmack CJ, Rose EA, Aaronson KD. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg. 1997;114:627–34.CrossRefPubMedGoogle Scholar
  17. 17.
    Chau EM, Bailey KR, Mahoney DW, Frantz RP, McGregor CG, Daly RC, Edwards BS, Olson LJ, Rodeheffer RJ. Predictors of reversibility of pulmonary hypertension in cardiac transplant recipients in the first postoperative year. Circulation. 1996;94:II267–72.PubMedGoogle Scholar
  18. 18.
    Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19:48–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Bhatia SJ, Kirshenbaum JM, Shemin RJ, Cohn LH, Collins JJ, Di Sesa VJ, Young PJ, Mudge Jr GH, Sutton MG. Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation. 1987;76:819–26.CrossRefPubMedGoogle Scholar
  20. 20.
    Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Butler J, Khadim G, Paul KM, Davis SF, Kronenberg MW, Chomsky DB, Pierson 3rd RN, Wilson JR. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol. 2004;43:787–93.CrossRefPubMedGoogle Scholar
  22. 22.
    Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113:1424–33.CrossRefPubMedGoogle Scholar
  23. 23.
    Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122:173–83.CrossRefPubMedGoogle Scholar
  24. 24.
    Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation. 1993;88:107–15.CrossRefPubMedGoogle Scholar
  25. 25.
    Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–16.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Figulla HR, Rahlf G, Nieger M, Luig H, Kreuzer H. Spontaneous hemodynamic improvement or stabilization and associated biopsy findings in patients with congestive cardiomyopathy. Circulation. 1985;71:1095–104.CrossRefPubMedGoogle Scholar
  27. 27.
    O’Connell JB, Costanzo-Nordin MR, Subramanian R, Robinson JA, Wallis DE, Scanlon PJ, Gunnar RM. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986;8:52–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK. Intermacs profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28:535–41.CrossRefPubMedGoogle Scholar
  29. 29.
    Zuckermann A, Dunkler D, Deviatko E, Bodhjalian A, Czerny M, Ankersmit J, Wolner E, Grimm M. Long-term survival (>10 years) of patients >60 years with induction therapy after cardiac transplantation. Eur J Cardiothorac Surg. 2003;24:283–91; discussion 291.CrossRefPubMedGoogle Scholar
  30. 30.
    Blanche C, Blanche DA, Kearney B, Sandhu M, Czer LS, Kamlot A, Hickey A, Trento A. Heart transplantation in patients seventy years of age and older: a comparative analysis of outcome. J Thorac Cardiovasc Surg. 2001;121:532–41.CrossRefPubMedGoogle Scholar
  31. 31.
    Oechslin E, Kiowski W, Schneider J, Follath F, Turina M, Gallino A. Pretransplant malignancy in candidates and post-transplant malignancy in recipients of cardiac transplantation. Ann Oncol. 1996;7:1059–63.CrossRefPubMedGoogle Scholar
  32. 32.
    DiSesa VJ, Sloss LJ, Cohn LH. Heart transplantation for intractable prosthetic valve endocarditis. J Heart Transplant. 1990;9:142–3.PubMedGoogle Scholar
  33. 33.
    Calabrese LH, Albrecht M, Young J, McCarthy P, Haug M, Jarcho J, Zackin R. Successful cardiac transplantation in an hiv-1-infected patient with advanced disease. N Engl J Med. 2003;348:2323–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Uriel N, Jorde UP, Cotarlan V, Colombo PC, Farr M, Restaino SW, Lietz K, Naka Y, Deng MC, Mancini D. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant. 2009;28:667–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1983;143:429–33.CrossRefPubMedGoogle Scholar
  36. 36.
    Young JN, Yazbeck J, Esposito G, Mankad P, Townsend E, Yacoub M. The influence of acute preoperative pulmonary infarction on the results of heart transplantation. J Heart Transplant. 1986;5:20–2.PubMedGoogle Scholar
  37. 37.
    Russo MJ, Chen JM, Hong KN, Stewart AS, Ascheim DD, Argenziano M, Mancini DM, Oz MC, Naka Y. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the united network of organ sharing database. Circulation. 2006;114:2280–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Bourge RC, Naftel DC, Costanzo-Nordin MR, Kirklin JK, Young JB, Kubo SH, Olivari MT, Kasper EK. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The transplant cardiologists research database group. J Heart Lung Transplant. 1993;12:549–62.PubMedGoogle Scholar
  39. 39.
    Grady KL, White-Williams C, Naftel D, Costanzo MR, Pitts D, Rayburn B, VanBakel A, Jaski B, Bourge R, Kirklin J. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices. Cardiac transplant research database (ctrd) group. J Heart Lung Transplant. 1999;18:750–63.CrossRefPubMedGoogle Scholar
  40. 40.
    Lietz K, John R, Burke EA, Ankersmit JH, McCue JD, Naka Y, Oz MC, Mancini DM, Edwards NM. Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. Transplantation. 2001;72:277–83.CrossRefPubMedGoogle Scholar
  41. 41.
    Clark AL, Knosalla C, Birks E, Loebe M, Davos CH, Tsang S, Negassa A, Yacoub M, Hetzer R, Coats AJ, Anker SD. Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changes. Eur J Heart Fail. 2007;9:839–44.CrossRefPubMedGoogle Scholar
  42. 42.
    Davies RR, Russo MJ, Yang J, Quaegebeur JM, Mosca RS, Chen JM. Listing and transplanting adults with congenital heart disease. Circulation. 2011;123:759–67.CrossRefPubMedGoogle Scholar
  43. 43.
    Karamlou T, Hirsch J, Welke K, Ohye RG, Bove EL, Devaney EJ, Gajarski RJ. A united network for organ sharing analysis of heart transplantation in adults with congenital heart disease: outcomes and factors associated with mortality and retransplantation. J Thorac Cardiovasc Surg. 2010;140:161–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Tjang YS, Tenderich G, Hornik L, Korfer R. Cardiac retransplantation in adults: an evidence-based systematic review. Thorac Cardiovasc Surg. 2008;56:323–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Topkara VK, Dang NC, John R, Cheema FH, Barbato R, Cavallo M, Liu JF, Liang LM, Liberman EA, Argenziano M, Oz MC, Naka Y. A decade experience of cardiac retransplantation in adult recipients. J Heart Lung Transplant. 2005;24:1745–50.CrossRefPubMedGoogle Scholar
  46. 46.
    John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, Edwards N, Rose E, Oz M, Itescu S. Intravenous immunoglobulin reduces anti-hla alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100:II229–35.CrossRefPubMedGoogle Scholar
  47. 47.
    Itescu S, Burke E, Lietz K, John R, Mancini D, Michler R, Rose E, Oz M, Edwards N. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation. 2002;105:1214–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Ulisney KL, Baldwin JT, Young JB. Third intermacs annual report: the evolution of destination therapy in the united states. J Heart Lung Transplant. 2011;30:115–23.CrossRefPubMedGoogle Scholar
  49. 49.
    Nativi JN, Drakos SG, Kucheryavaya AY, Edwards LB, Selzman CH, Taylor DO, Hertz MI, Kfoury AG, Stehlik J. Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the international society for heart and lung transplantation. J Heart Lung Transplant. 2011;30:854–61.PubMedGoogle Scholar
  50. 50.
    Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, Webb JG, Steingart R, Picard MH, Menegus MA, Boland J, Sanborn T, Buller CE, Modur S, Forman R, Desvigne-Nickens P, Jacobs AK, Slater JN, LeJemtel TH. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190–2.CrossRefPubMedGoogle Scholar
  51. 51.
    Burkhoff D, Cohen H, Brunckhorst C, O’Neill WW. A randomized multicenter clinical study to evaluate the safety and efficacy of the tandemheart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152:469.e1–8.CrossRefGoogle Scholar
  52. 52.
    Pulido JN, Park SJ, Rihal CS. Percutaneous left ventricular assist devices: clinical uses, future applications, and anesthetic considerations. J Cardiothorac Vasc Anesth. 2010;24:478–86.CrossRefPubMedGoogle Scholar
  53. 53.
    Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J, Kastrati A, Schomig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Thiele H, Smalling RW, Schuler GC. Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2007;28:2057–63.CrossRefPubMedGoogle Scholar
  55. 55.
    Kittleson MM, Patel JK, Moriguchi JD, Kawano M, Davis S, Hage A, Hamilton MA, Esmailian F, Kobashigawa JA. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. J Heart Lung Transplant. 2011;30(11):1250–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Sassard T, Scalabre A, Bonnefoy E, Sanchez I, Farhat F, Jegaden O. The right axillary artery approach for the impella recover lp 5.0 microaxial pump. Ann Thorac Surg. 2008;85:1468–70.CrossRefPubMedGoogle Scholar
  57. 57.
    Haj-Yahia S, Birks EJ, Amrani M, Petrou M, Bahrami T, Dreyfus G, Khaghani A. Bridging patients after salvage from bridge to decision directly to transplant by means of prolonged support with the centrimag short-term centrifugal pump. J Thorac Cardiovasc Surg. 2009;138:227–30.CrossRefPubMedGoogle Scholar
  58. 58.
    John R, Liao K, Lietz K, Kamdar F, Colvin-Adams M, Boyle A, Miller L, Joyce L. Experience with the levitronix centrimag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg. 2007;134:351–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.CrossRefPubMedGoogle Scholar
  60. 60.
    Miller LW. Is pulsatile blood flow no longer essential? Circulation. 2009;120:2313–4.CrossRefPubMedGoogle Scholar
  61. 61.
    John R, Boyle A, Pagani F, Miller L. Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices. J Cardiovasc Transl Res. 2009;2:154–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, Klodell Jr CT, Boyle AJ, John R, Chen L, Massey HT, Farrar DJ, Conte JV. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the heartmate ii left ventricular assist device. Circulation. 2009;120:2352–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado 3rd RM, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefPubMedGoogle Scholar
  64. 64.
    Copeland JG, Smith RG, Arabia FA, Nolan PE, McClellan D, Tsau PH, Sethi GK, Bose RK, Banchy ME, Covington DL, Slepian MJ. Total artificial heart bridge to transplantation: a 9-year experience with 62 patients. J Heart Lung Transplant. 2004;23:823–31.CrossRefPubMedGoogle Scholar
  65. 65.
    Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, Conte JV, Naka Y, Mancini D, Delgado RM, MacGillivray TE, Farrar DJ, Frazier OH. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMedGoogle Scholar
  66. 66.
    Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, Conte JV, Bogaev RC, MacGillivray TE, Naka Y, Mancini D, Massey HT, Chen L, Klodell CT, Aranda JM, Moazami N, Ewald GA, Farrar DJ, Frazier OH. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–21.CrossRefPubMedGoogle Scholar
  67. 67.
    Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevanandam V, Anderson AS, Kormos RL, Teuteberg JJ, Levy WC, Naftel DC, Bittman RM, Pagani FD, Hathaway DR, Boyce SW. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125(25):3191–200.CrossRefPubMedGoogle Scholar
  68. 68.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier HO; the HeartMate II Investigators. N Engl J Med. 2009;361(23):2241–51.Google Scholar
  69. 69.
    Slaughter MS, Tsui SS, El-Banayosy A, Sun BC, Kormos RL, Mueller DK, Massey HT, Icenogle TB, Farrar DJ, Hill JD. Results of a multicenter clinical trial with the thoratec implantable ventricular assist device. J Thorac Cardiovasc Surg. 2007;133:1573–80.CrossRefPubMedGoogle Scholar
  70. 70.
    Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, Starling RC, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1–39.CrossRefPubMedGoogle Scholar
  71. 71.
    Russo MJ, Hong KN, Davies RR, Chen JM, Sorabella RA, Ascheim DD, Williams MR, Gelijns AC, Stewart AS, Argenziano M, Naka Y. Post-transplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;138:1425–32.e1-3.CrossRefPubMedGoogle Scholar
  72. 72.
    Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, Gelijns AC, Hong KN, Teuteberg JJ. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative intermacs classification. J Heart Lung Transplant. 2011;30:402–7.Google Scholar
  73. 73.
    Bull DA, Reid BB, Selzman CH, Mesley R, Drakos S, Clayson S, Stoddard G, Gilbert E, Stehlik J, Bader F, Kfoury A, Budge D, Eckels DD, Fuller A, Renlund D, Patel AN. The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation. J Thorac Cardiovasc Surg. 2010;140:169–73.Google Scholar
  74. 74.
    Patlolla V, Patten RD, Denofrio D, Konstam MA, Krishnamani R. The effect of ventricular assist devices on post-transplant mortality an analysis of the united network for organ sharing thoracic registry. J Am Coll Cardiol. 2009;53:264–71.Google Scholar
  75. 75.
    Holman WL, Kormos RL, Naftel DC, Miller MA, Pagani FD, Blume E, Cleeton T, Koenig SC, Edwards L, Kirklin JK. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant. 2009;28:44–50.Google Scholar
  76. 76.
    Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-rematch era: implications for patient selection. Circulation. 2007;116:497–505.CrossRefPubMedGoogle Scholar
  77. 77.
    Holman WL, Kirklin JK, Naftel DC, Kormos RL, Desvign-Nickens P, Camacho MT, Ascheim DD. Infection after implantation of pulsatile mechanical circulatory support devices. J Thorac Cardiovasc Surg. 2010;139:1632–6.e2.CrossRefPubMedGoogle Scholar
  78. 78.
    Cleveland Jr JC, Naftel DC, Reece TB, Murray M, Antaki J, Pagani FD, Kirklin JK. Survival after biventricular assist device implantation: an analysis of the interagency registry for mechanically assisted circulatory support database. J Heart Lung Transplant. 2011;30:862–9.PubMedGoogle Scholar
  79. 79.
    Fitzpatrick 3rd JR, Frederick JR, Hiesinger W, Hsu VM, McCormick RC, Kozin ED, Laporte CM, O’Hara ML, Howell E, Dougherty D, Cohen JE, Southerland KW, Howard JL, Paulson EC, Acker MA, Morris RJ, Woo YJ. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137:971–7.PubMedCentralCrossRefPubMedGoogle Scholar
  80. 80.
    Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–72.PubMedCentralCrossRefPubMedGoogle Scholar
  81. 81.
    Schaffer JM, Arnaoutakis GJ, Allen JG, Weiss ES, Patel ND, Russell SD, Shah AS, Conte JV. Bleeding complications and blood product utilization with left ventricular assist device implantation. Ann Thorac Surg. 2011;91:740–7; discussion 747–9.CrossRefPubMedGoogle Scholar
  82. 82.
    Demirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, Bogaev RC, Frazier OH. Arteriovenous malformation and gastrointestinal bleeding in patients with the heartmate ii left ventricular assist device. J Heart Lung Transplant. 2011;30:849–53.PubMedGoogle Scholar
  83. 83.
    Frazier OH. Unforeseen consequences of therapy with continuous-flow pumps. Circ Heart Fail. 2010;3:647–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005;24:105–9.CrossRefPubMedGoogle Scholar
  85. 85.
    Crow S, John R, Boyle A, Shumway S, Liao K, Colvin-Adams M, Toninato C, Missov E, Pritzker M, Martin C, Garry D, Thomas W, Joyce L. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137:208–15.CrossRefPubMedGoogle Scholar
  86. 86.
    Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Pepin Heart InstituteTampaUSA
  2. 2.Department of CardiologyUniversity of KentuckyLexingtonUSA

Personalised recommendations